Cipla Limited (NSE:CIPLA)
1,328.40
+15.40 (1.17%)
Jan 28, 2026, 3:30 PM IST
Cipla Revenue
Cipla had revenue of 69.63B INR in the quarter ending December 31, 2025, with 0.02% growth. This brings the company's revenue in the last twelve months to 279.67B, up 4.67% year-over-year. In the fiscal year ending March 31, 2025, Cipla had annual revenue of 272.67B with 6.78% growth.
Revenue (ttm)
279.67B
Revenue Growth
+4.67%
P/S Ratio
3.79
Revenue / Employee
9.23M
Employees
30,313
Market Cap
1.06T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 272.67B | 17.31B | 6.78% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Zydus Lifesciences | 244.94B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |
| Divi's Laboratories | 100.29B |
| Ipca Laboratories | 93.59B |
Cipla News
- 2 days ago - Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues - NDTV
- 4 days ago - Cipla Ltd (BOM:500087) Q3 2026 Earnings Call Highlights: Strategic Growth Amidst Margin Challenges - GuruFocus
- 4 days ago - Q3 2026 Cipla Ltd Earnings Call Transcript - GuruFocus
- 5 days ago - Cipla shares fall sharply over 3% as Q3 Net profit drops 57.4% YoY to Rs 674.56 crore, EBITDA down 36.7% - Business Upturn
- 5 days ago - Cipla Q3 Results: Net profit falls 57.4% YoY to Rs 674.56 crore, revenue flat at Rs 7,074.48 crore - Business Upturn
- 5 days ago - Top Q3 results today, January 23: Adani Green, IndusInd Bank, Cipla, Godrej Consumer Products, JSW Steel and more to announce earnings - Business Upturn
- 9 days ago - Pharma sector stocks fall today: Cipla drops 1.52%, Divi’s Laboratories falls 0.78%, Alembic Pharma down 0.52% - Business Upturn
- 12 days ago - Nifty 50 top losers today, January 16: Eternal, Jio Financial Services, Cipla, Hindalco, Asian Paints and more - Business Upturn